Shiqing Chen

机构：Malaysian Palm Oil Board, Shanghai Medical College of Fudan University, Shanghai Jiao Tong University, Ministry of Education · ORCID：0000-0002-7544-9916

发表论文 115 篇 · 总被引 1805 次 · h-index 19

代表论文

• Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial (2023 · Journal for ImmunoTherapy of Cancer · 被引 131)
• Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial (2023 · Nature Communications · 被引 49)
• Confinement in Dual-Chain-Locked DNA Origami Nanocages Programs Marker-Responsive Delivery of CRISPR/Cas9 Ribonucleoproteins (2023 · Journal of the American Chemical Society · 被引 45)
• First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study (2024 · Signal Transduction and Targeted Therapy · 被引 43)
• Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study (2023 · Annals of Surgical Oncology · 被引 16)
• Vaccarin alleviates cisplatin-induced acute kidney injury via decreasing NOX4-derived ROS (2023 · Heliyon · 被引 14)